GLOBAL DEAL SYNDICATION
HBS Alumni Angels syndicates selected deals across the full global membership of its 14 chapters. This enables selected deals from one chapter to reach a global network of accredited investor alumni. This is a unique benefit of being a member in a local HBS Alumni Angel chapter. Investment decisions are made and executed individually following a global webinar. Once investments are made, investors often assist companies in other areas as formal or informal advisers. For details on how the process works, please scroll down.
UPCOMING SYNDICATION CALLS
SAVE THE DATE
GLOBAL SYNDICATED INVESTMENT PRESENTATION:
MOXIE SCRUBS
SAVE THE DATE
Thursday, June 5, 2025 9am PT, 12pm ET, 5pm London, 6pm Continental Europe
Presenter:
CEO & Founder, Alicia Tulsee, MBA'15
​
For HBS Angels Members ONLY
On behalf of the Boston chapter, we would like to share the following investment opportunity:
​
The first and only brand inspired and designed by nurses, Moxie Scrubs is proud to be a woman-owned, minority-owned Boston-based start-up, born in a taxi cab and Harvard’s Innovation Lab.
MORE INFORMATION COMING SOON!
​
Alicia Tulsee
FOUNDER & CEO, HBS MBA 2015
Alicia Tulsee is a native New Yorker and Harvard alum based in Boston, MA and is the founder of the first direct to consumer medical apparel brand for nurses, Moxie Scrubs. Alicia graduated from Harvard University with a degree in economics in 2015 and has expertise in consumer packaged goods, entertainment, and nonprofits. Alicia previously spearheaded national marketing for brands like Budweiser and AB InBev portfolio brands in emerging markets, FreshPure Waters, and others. In the music industry, Alicia worked in event planning and management, copy-writing, working directly with artists.
In awe of all of the amazing nurses who cared for her loved ones, Alicia felt a calling to do something meaningful for the nursing profession and founded Moxie Scrubs out of Harvard University’s Innovation Lab with the passion to create a brand dedicated to giving nurses the sense of fashion, professionalism, and respect that they want and deserve.
Today, Alicia has received acclaim as an impact entrepreneur in Forbes, ForbesWomen, Nasdaq, Entrepreneur Magazine, and others.
The Zoom Meeting information will be in your registration confirmation email.
Please check your junk/spam/bulk folders if you don't see it.
PREVIOUS SYNDICATION CALL
GLOBAL SYNDICATED INVESTMENT PRESENTATION:
OSTEOBOOST
Thursday, April 10, 2025 9am PT, 12pm ET, 5pm London, 6pm Continental Europe
Presenter:
CEO & President, Laura Yecies, MBA'88
​
For HBS Angels Members ONLY
On behalf of the New York chapter, we would like to share the following investment opportunity:
​
Osteoboost is a precision vibration therapy medical device, clinically-proven to slow the loss of bone density and strength in postmenopausal women with osteopenia. Osteoboost is the first FDA-cleared prescription non-drug treatment for low bone density.
Company Overview:
At Osteoboost Health, we develop breakthrough solutions to help people defend against osteoporosis and osteopenia. Our mission is simple: to empower people to lead longer, stronger, and more active lives by safeguarding bone density from the effects of menopause, aging, cancer, and other degenerative causes of bone loss.
Our flagship product, Osteoboost, is a new way of thinking about an age-old problem: low bone density. It’s a prescription medical device, worn around the hips, that delivers clinically-proven targeted vibration therapy directly to the areas of the body most at risk of life-altering osteoporotic fractures. Osteoboost includes a comprehensive digital solution, including the recently acquired Wellen osteoporosis exercise program.
Osteoboost is an FDA-cleared treatment indicated for postmenopausal women with osteopenia. It fills a critical vacuum in the low bone density treatment and prevention space, and is drug-free, pain-free, and convenient for patients to use in their daily life.
​
Efficacy:
In a gold-standard double-blinded sham-controlled clinical trial at the University of Nebraska Medical Center, Osteoboost reduced the loss of bone strength in the vertebral spine by 83%, reduced the loss of bone density in the spine by 85%, and reduced the loss of bone density in the hips by 55%. The FDA cleared Osteoboost as a Class II Breakthrough Device through the De Novo pathway in 2024.
Sales Highlights To Date:
In November of 2024, we opened pre-orders to our waiting list, selling >1000 devices for over $1M in collected revenue. Over 950 unique medical providers have prescribed Osteoboost, some as many as 37 times (in 4 months) and physicians from more than 30 leading academic medical centers have prescribed. Osteoboost is expected to launch publicly in mid-April, 2025.
​
Financial and Business Projections:
$5M revenue 2025
$24M revenue 2026
$62M revenue, cash flow positive 2027.
Executive Team:
Our executive team offers deep business, scientific, and medical experience
-
CEO: Laura Yecies, MBA from Harvard, MSFS Georgetown
-
Chief Scientific Officer: Michael Jaasma, PhD in orthopedic biomechanics, UC Berkeley
-
Chief Medical Officer: Dr. Pamela Peeke, MD, MPH, FACP, FACSM, UC Berkeley, UC Davis
Raise :
$3.5M SAFE, 20% Discount, $35M Post Money CAP. We have raised $2.8M closed.
Laura Yecies
CO-FOUNDER & CEO, HBS MBA 1988
​Osteoboost CEO Laura Yecies is a healthtech leader and strategist with deep experience launching and scaling medical device and diagnostic companies. Prior to Osteoboost, she was CEO of NeuroSync, Catch (acq. by Apple), and SugarSync (acq J2Global). She holds an MBA from Harvard, MSFS from Georgetown, and AB from Dartmouth. Yecies is a highly-regarded speaker, podcaster, and writer on healthcare and technology.
PAST SYNDICATED COMPANIES
 |  |  |
|---|---|---|
 |  |  |
 |  |  |
 |  |  |
 |  |  |
 | |  |
|  | |
 |  |  |
 |  |  |
 |  |  |
 | |  |
 |  |  |
 |  |  |
 |  |  |
 |  |  |
 |  |  |
 |  |  |
 |  |
HOW IT WORKS
Use arrows on the side to navigate
1. HOST CHAPTER
A company must meet a threshold of member investment in one of our HBS Alumni Angel Chapters listed here. The leadership of the host chapter nominates the company for global syndication and provides a local member contact to act as syndication lead and a company contact.
CRITERIA
Ideally, for global syndication a company should meet the following requirements:
-
Local host chapter members committed to invest at least $50,000* and local chapter forwards deal to global for syndication;
-
Company assures at least $50,000-100,000 investible capacity;
-
Company provides at least 2 weeks for due diligence following the webinar, prior to requiring an investment decision;
-
Minimum individual investment amount is set at $25,000 or less;
-
Company agrees to a one-time admin fee of $1500.
The Global Syndication Committee selects the most suitable company candidates from the 15 participating HBSAA chapters and is aiming to host monthly webinars.
​
*NY and other larger chapters may have a $100,000 min.